 |
0 Diseases |  |
5 Trials |
|
5 Trials |  |
77 News |  |
| «12 |
- | Infimab (infliximab biosimilar) / Sun Pharma, Reliance Life Sciences, BCD-055 (infliximab biosimilar) / Biocad
Journal: The Experience With Biosimilars Of Infliximab In Rheumatic Diseases. (Pubmed Central) - Aug 1, 2019
In addition, the European experience has proved the economic advantages of the incorporation of infliximab biosimilars in clinical practice. Despite the widespread use of infliximab biosimilars there is still a lack of data regarding interchangeability between reference products and biosimilars.
- || ABP 710 (infliximab biosimilar) / Amgen
#Amgen Pulls European Application for Its #Biosimilar #Infliximab ABP 710 https://t.co/Vj40mfRNRl via @BiosimCenter @Amgen #Remicade #biologics #biosimilarnews (Twitter) - Jul 3, 2019
- ||||||| Avsola (infliximab-axxq) / Amgen
Trial completion: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab (clinicaltrials.gov) - Aug 17, 2018
P3, N=558, Completed, Sponsor: Amgen
Despite the widespread use of infliximab biosimilars there is still a lack of data regarding interchangeability between reference products and biosimilars. Active, not recruiting --> Completed
- ||||| Avsola (infliximab-axxq) / Amgen
Enrollment closed: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab (clinicaltrials.gov) - Aug 24, 2017
P3, N=558, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Avsola (infliximab-axxq) / Amgen
Trial primary completion date: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab (clinicaltrials.gov) - Jan 30, 2017
P3, N=550, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2018 --> Apr 2018
- |||||||||| Avsola (infliximab-axxq) / Amgen
New P3 trial: Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab (clinicaltrials.gov) - Oct 27, 2016
P3, N=550, Recruiting, Sponsor: Amgen